Lešin Gaćina Dina, Vidović Tomislav, Vlajić Oreb Nikolina, Matković Lovorka, Jandroković Sonja
Department of Ophthalmology, Zagreb University Hospital Center, 10 000 Zagreb, Croatia.
Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, Merkur University Hospital, 10 000 Zagreb, Croatia.
Reports (MDPI). 2025 Aug 20;8(3):149. doi: 10.3390/reports8030149.
: Ischemic optic neuropathies (IONs) are significant causes of vision loss resulting from compromised blood flow to the optic nerve. Diabetes mellitus (DM) exacerbates the risk of IONs through chronic hyperglycemia and associated vascular dysfunction. Recently, semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been linked to ocular complications, including non-arteritic anterior ischemic optic neuropathy (NAION), potentially due to the rapid glycemic changes or vascular effects. : A 55-year-old female with type 2 DM, hypertension, and hyperlipidemia presented with blurred vision and optic disc edema after four months of semaglutide therapy (Ozempic, Sydney, Australia). Initially diagnosed with diabetic papillopathy (DP), her condition progressed to NAION, leading to partial visual recovery with corticosteroid treatment and improved glycemic management. Diagnostic evaluations, including visual field testing, optical coherence tomography, and fluorescein angiography, supported the diagnosis. : This case report describes the clinical course of a diabetic patient treated with a semaglutide who developed an ischemic optic event. The timing of symptom onset in relation to the initiation of semaglutide therapy raises the possibility of a causal association between the drug and this rare ocular complication. Close monitoring of ocular health is crucial for patients on GLP-1 receptor agonists, particularly those with pre-existing vascular risk factors. Further research is needed to elucidate the underlying mechanisms and guide clinical practice.
缺血性视神经病变（IONs）是因视神经血流受损导致视力丧失的重要原因。糖尿病（DM）通过慢性高血糖和相关血管功能障碍加剧了IONs的风险。最近，司美格鲁肽，一种胰高血糖素样肽-1（GLP-1）受体激动剂，与眼部并发症有关，包括非动脉性前部缺血性视神经病变（NAION），这可能是由于血糖的快速变化或血管效应所致。：一名55岁的2型糖尿病、高血压和高脂血症女性患者，在接受司美格鲁肽治疗（Ozempic，澳大利亚悉尼）四个月后出现视力模糊和视盘水肿。最初被诊断为糖尿病性视乳头病变（DP），她的病情进展为NAION，经皮质类固醇治疗和改善血糖管理后视力部分恢复。包括视野测试、光学相干断层扫描和荧光素血管造影在内的诊断评估支持了这一诊断。：本病例报告描述了一名接受司美格鲁肽治疗的糖尿病患者发生缺血性视神经事件的临床过程。症状出现的时间与司美格鲁肽治疗开始的时间关系，增加了该药物与这种罕见眼部并发症之间存在因果关联的可能性。对使用GLP-1受体激动剂的患者，尤其是那些有血管危险因素的患者，密切监测眼部健康至关重要。需要进一步研究以阐明潜在机制并指导临床实践。
